Reporting owner · CIK 0001450324
Equels Thomas K
SEC Form 4 history across 1 companies, 5 transactions and 5 filings.
CEO, PRESCEO & PresidentAIM ImmunoTech Inc.
Open-market transaction mix100% buys5 buys · 0 sales
Available history · Sep 15, 2026 – Oct 23, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
AIMAIM ImmunoTech Inc. | Equels Thomas KCEO · PRES | P · buySEC filing ↗ | $5.06kView disclosure → | |
AIMAIM ImmunoTech Inc. | Equels Thomas KCEO · PRES | P · buySEC filing ↗ | $5.09kView disclosure → | |
AIMAIM ImmunoTech Inc. | Equels Thomas KCEO · PRES | P · buySEC filing ↗ | $4.99kView disclosure → | |
AIMAIM ImmunoTech Inc. | Equels Thomas KCEO · PRES | P · buySEC filing ↗ | $2.31kView disclosure → | |
AIMAIM ImmunoTech Inc. | Equels Thomas KCEO · PRES | P · buySEC filing ↗ | $4.86kView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
buy at AIM ImmunoTech Inc. on Oct 23, 2026 valued at $5,068.
Review SEC filingLatest sale
No open-market insider sale is available.
Monthly open-market activity
Last 2 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Sep 2026 | 3 | 0 | $12,164.00 | $0.00 | $12,164.00 |
| Oct 2026 | 2 | 0 | $10,161.75 | $0.00 | $10,161.75 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$4.5K
Median P/S size$5K
Direct5
Indirect0
Oct 23, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
5 observations · Sep 15, 2026 – Oct 23, 2026. Window ends at the latest available report, not today.
Selected observation · Oct 23, 2026189,747 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 15, 2026 | 91,822 | Sep 16, 2026 | View transaction |
| Sep 16, 2026 | 102,822 | Sep 17, 2026 | View transaction |
| Sep 17, 2026 | 126,822 | Sep 18, 2026 | View transaction |
| Oct 22, 2026 | 158,072 | Oct 23, 2026 | View transaction |
| Oct 23, 2026 | 189,747 | Oct 26, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Equels Thomas K Insider Activity FAQ
SEC Form 4 context
Who is Equels Thomas K?
Equels Thomas K is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001450324.
Which companies has Equels Thomas K reported transactions for?
AIM ImmunoTech Inc.
When was Equels Thomas K's latest insider buy?
buy at AIM ImmunoTech Inc. on Oct 23, 2026 valued at $5,068.
When was Equels Thomas K's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.